RecruitingNot ApplicableNCT07054489
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Using Polygenic Scores to Guide Beta-blocker Therapy for Heart Failure With Mildly Reduced Ejection Fraction
Sponsor
David Lanfear
Enrollment
10 participants
Start Date
Nov 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
Eligibility
Min Age: 18 YearsMax Age: 89 Years
Inclusion Criteria3
- Age 18-89 years
- Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
- Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
Exclusion Criteria13
- Unable to provide informed consent
- Previous documented EF =\< 35%
- Currently on BB \>25% target dose
- Uncontrolled hypertension (systolic BP \> 180 at enrollment)
- Has contraindications to all BB or intolerance to metoprolol
- Systolic BP \< 100 or heart rate \<70
- Current cancer requiring active treatment
- Heart transplant or LVAD or expected in the next year
- Life expectancy \< 1 year for any reason
- Dialysis dependence or ESRD
- MI/ PCI/ CABG within 90 days prior to enrollment or planned in the future
- Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
- If PI decides for any reason participation in trial is not in best interest of the patient
Interventions
OTHERBeta blocker
Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07054489
Related Trials
Mind Your Heart-II
NCT054311921 location
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370641 locations
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT0700216420 locations
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288652 locations
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
NCT071917301 location